These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 19852689

  • 1. Clinical management of clopidogrel inefficiency by point of care platelet function testing and individual adjustment of anti-platelet therapy--initial experiences.
    Schuhmann CG, Sohn HY, Nagel J, Spannagl M, Klauss V, Krötz F.
    Platelets; 2009 Nov; 20(7):498-504. PubMed ID: 19852689
    [Abstract] [Full Text] [Related]

  • 2. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
    Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N.
    J Am Coll Cardiol; 2009 Mar 10; 53(10):849-56. PubMed ID: 19264241
    [Abstract] [Full Text] [Related]

  • 3. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
    Angiolillo DJ, Bernardo E, Palazuelos J, Desai B, Weisberg I, Alfonso F, Guzman LA, Hernández-Antolin R, Zenni MZ, Macaya C, Fernandez-Ortiz A, Bass TA.
    Thromb Haemost; 2008 Jan 10; 99(1):161-8. PubMed ID: 18217149
    [Abstract] [Full Text] [Related]

  • 4. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S, Roe MT.
    Cardiovasc Drug Rev; 2007 Jan 10; 25(2):188-203. PubMed ID: 17614940
    [Abstract] [Full Text] [Related]

  • 5. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E, PRINCIPLE-TIMI 44 Investigators.
    Circulation; 2007 Dec 18; 116(25):2923-32. PubMed ID: 18056526
    [Abstract] [Full Text] [Related]

  • 6. [Optimal platelet inhibition after coronary stent implantation. Current status].
    Silber S, Hoffmeister HM, Bode C.
    Herz; 2008 Jun 18; 33(4):244-53. PubMed ID: 18581073
    [Abstract] [Full Text] [Related]

  • 7. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
    Montalescot G, Sideris G, Cohen R, Meuleman C, Bal dit Sollier C, Barthélémy O, Henry P, Lim P, Beygui F, Collet JP, Marshall D, Luo J, Petitjean H, Drouet L.
    Thromb Haemost; 2010 Jan 18; 103(1):213-23. PubMed ID: 20062936
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
    Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E, JUMBO-TIMI 26 Investigators.
    Circulation; 2005 Jun 28; 111(25):3366-73. PubMed ID: 15967851
    [Abstract] [Full Text] [Related]

  • 11. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
    Cuisset T, Frere C, Quilici J, Gaborit B, Castelli C, Poyet R, Bali L, Morange PE, Alessi MC, Bonnet JL.
    Am J Cardiol; 2009 Oct 15; 104(8):1078-82. PubMed ID: 19801028
    [Abstract] [Full Text] [Related]

  • 12. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.
    Angiolillo DJ, Costa MA, Shoemaker SB, Desai B, Bernardo E, Suzuki Y, Charlton RK, Zenni MM, Guzman LA, Bass TA.
    Am J Cardiol; 2008 Feb 15; 101(4):440-5. PubMed ID: 18312754
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study.
    Collet JP, Silvain J, Landivier A, Tanguy ML, Cayla G, Bellemain A, Vignolles N, Gallier S, Beygui F, Pena A, Montalescot G.
    Circulation; 2008 Sep 16; 118(12):1225-33. PubMed ID: 18765393
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ.
    Thromb Haemost; 2008 Jan 16; 99(1):215-22. PubMed ID: 18217157
    [Abstract] [Full Text] [Related]

  • 20. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV, Papathanasiou AI, Elisaf M, Goudevenos JA, Tselepis AD.
    Platelets; 2005 Aug 16; 16(5):287-92. PubMed ID: 16011979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.